Lonhala Magnair Approved As First Nebulized Long-acting Muscarinic Antagonist for COPD
On December 5, 2017, the United States Food and Drug Administration (FDA) announced approval of a long-acting nebulized bronchodilator called Lonhala Magnair. Lonhala is the brand name of the medication, while the generic name is glycopyrrolate. It is also known as SUN-101/eFlow®. Magnair is the brand name of the eFlow® nebulizer system developed by PARI Pharma GmbH.
According to the FDA, Lonhala Magnair is indicated for “long term, twice each day (morning and evening) maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.”
It is the first long-acting muscarinic antagonist (LAMA) bronchodilator available in a solution to be used in a nebulizer. The Magnair nebulizer is a silent and portable delivery device that reduces the amount of time required for someone with COPD to inhale the medication in two to three minutes.
Nebulized medications offer an alternative to metered-dose inhalers, soft mist inhalers, and dry powder inhalers. They allow a person to breathe normally in and out while inhaling the medicine.
My Comments Lonhala Magnair is the first long-acting muscarinic antagonist bronchodilator available for the nebulized treatment of those with COPD. There are two long- acting nebulized beta-agonist bronchodilators available – Brovana and Perforomist. Both last 12 hours, are used twice daily, and are used with a jet nebulizer.
I expect that Lonhala will be used in addition to Brovana or Perforomist to provide more effective opening of the breathing tubes (bronchodilation) when nebulization is used.